TY - JOUR
T1 - Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage
AU - Palle, J
AU - Frost, B M
AU - Forestier, E
AU - Gustafsson, G
AU - Nygren, P
AU - Hellebostad, M
AU - Jonsson, O G
AU - Kanerva, J
AU - Schmiegelow, K
AU - Larsson, R
AU - Lönnerholm, G
AU - Nordic Society for Paediatric Haematology and Oncology
PY - 2005/4
Y1 - 2005/4
N2 - Rearrangements in the 11q23 region, the site of the mixed lineage leukaemia (MLL) gene, are found in both childhood acute myeloid (AML) and lymphoblastic (ALL) leukaemia. We studied the in vitro drug resistance by the fluorometric microculture cytotoxicity assay (FMCA) in 132 children with AML and 178 children with ALL (aged 0-17 years). In AML, children with t(9;11) (n = 10) were significantly more sensitive to cytarabine (P < 0.001) and doxorubicin (P = 0.005) than non-11q23 rearranged patients (n = 108). Children with other 11q23 rearrangements (n = 14) differed less from non-rearranged children. The 'AML-profile' common to all three groups included relative resistance to glucocorticoids and vincristine. In ALL, children with 11q23 rearrangement (n = 22) were significantly more sensitive to cytarabine (P = 0.026) than children without 11q23 rearrangement (n = 156), also after stratification for white blood cell count. In conclusion, the findings indicate that the cellular drug resistance is correlated to both the cell lineage and the type of 11q23 rearrangement. High cellular sensitivity to cytarabine and doxorubicin might explain the excellent treatment results in children with AML and t(9;11). The present study supports the strategy of contemporary protocols to include high-dose cytarabine in the treatment of 11q23-positive patients both in AML and ALL.
AB - Rearrangements in the 11q23 region, the site of the mixed lineage leukaemia (MLL) gene, are found in both childhood acute myeloid (AML) and lymphoblastic (ALL) leukaemia. We studied the in vitro drug resistance by the fluorometric microculture cytotoxicity assay (FMCA) in 132 children with AML and 178 children with ALL (aged 0-17 years). In AML, children with t(9;11) (n = 10) were significantly more sensitive to cytarabine (P < 0.001) and doxorubicin (P = 0.005) than non-11q23 rearranged patients (n = 108). Children with other 11q23 rearrangements (n = 14) differed less from non-rearranged children. The 'AML-profile' common to all three groups included relative resistance to glucocorticoids and vincristine. In ALL, children with 11q23 rearrangement (n = 22) were significantly more sensitive to cytarabine (P = 0.026) than children without 11q23 rearrangement (n = 156), also after stratification for white blood cell count. In conclusion, the findings indicate that the cellular drug resistance is correlated to both the cell lineage and the type of 11q23 rearrangement. High cellular sensitivity to cytarabine and doxorubicin might explain the excellent treatment results in children with AML and t(9;11). The present study supports the strategy of contemporary protocols to include high-dose cytarabine in the treatment of 11q23-positive patients both in AML and ALL.
KW - Acute Disease
KW - Adolescent
KW - Antineoplastic Agents/pharmacology
KW - Cell Lineage
KW - Child
KW - Child, Preschool
KW - Chromosomes, Human, Pair 11
KW - Chromosomes, Human, Pair 9
KW - Cytarabine/pharmacology
KW - Cytotoxicity Tests, Immunologic
KW - DNA-Binding Proteins/genetics
KW - Doxorubicin/pharmacology
KW - Drug Resistance, Neoplasm/genetics
KW - Female
KW - Fluorometry
KW - Gene Rearrangement
KW - Glucocorticoids/pharmacology
KW - Histone-Lysine N-Methyltransferase
KW - Humans
KW - Infant
KW - Infant, Newborn
KW - Leukemia, Myeloid/genetics
KW - Male
KW - Myeloid-Lymphoid Leukemia Protein
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
KW - Prospective Studies
KW - Proto-Oncogenes/genetics
KW - Statistics, Nonparametric
KW - Transcription Factors/genetics
KW - Translocation, Genetic
U2 - 10.1111/j.1365-2141.2005.05433.x
DO - 10.1111/j.1365-2141.2005.05433.x
M3 - Journal article
C2 - 15813846
SN - 0007-1048
VL - 129
SP - 189
EP - 198
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 2
ER -